pharma news

Wave Life Sciences has recently announced the discontinuation of its drug suvodirsen, for the treatment of a rare Duchenne Muscular Dystrophy mutation.  Duchenne Muscular Dystrophy is a progressive worsening of the skeletal and heart muscles resulting in weakness. The disorder, is due to deficient prot...

A leading global international investment firm, Omega Funds has announced the closure of its sixth fundraising USD 438 Million. More than decade old Life Sciences-based investment firm specialized in direct secondary transactions, Omega funds focuses in investing in Life Sciences vertical, aiming to fulfil the ...

Merck is set to complete the already planned purchase of the ArQule for USD 2.7 Billion. Under the terms of the agreement, Merck will pay USD 20 for each share in cash for a total amount of USD 2.7 Billion. ArQule is a biopharmaceutical, which is focused on kinase inhibitor discovery, finding cures for cancer p...

Cumberland Pharmaceuticals has recently received approval from the US FDA for its RediTrex injection for the treatment of rheumatoid arthritis. Cumberland pharmaceuticals pharma company focusing on acquiring and commercializing prescription products has gained access to the injection from Nordic Group two years...

Sanofi’s Toujeo has received FDA recommendation for its expanded use in Type 1 Diabetes. Toujeo is an insulin glargine injection to control the highs and lows of blood sugar in the body. Indicated to be used in adults and paediatric patients of age six and older. Earlier, the injection was considered suitab...

Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market. Under the terms of the deal, Novartis will pay USD 85 per share to the Medicines Company, a cholesterol drug developer, making the deal up to USD 9.7 Billion. The whole...

Novo Nordisk has announced to enter into a collaboration with Dicerna’s RNAi platform to focus on metabolic and liver-related diseases. The companies will be focusing to advance the treatment landscape of the diseases such as non-alcoholic steatohepatitis (NASH), Type 2 diabetes and obesity. Nordisk will be inv...

AbbVie has traded off its bonds worth USD 30 Billion to finance the purchase of the Allergan.   AbbVie this year in June has agreed to buy Allergan for USD 63 Billion, which is one of the largest deals this year. The acquisition will help AbbVie to diversify its drug portfolio which mostly revolves around H...

The US FDA for the third time has refused to give approval to Lipocine’s oral testosterone drug, Tlando. The drug is an oral testosterone replacement therapy in clinical trials for the treatment of Primary and Secondary hypogonadism in males. The drug contains containing Testosterone Undecanoate (TU) which help...

Switzerland-based Vifor Pharma and Germany-based Evotech AG have collaborated for the development and discovery of new treatments for kidney diseases. The launch of a new 50:50 joint venture will be focused on developing nephrology pipeline utilizing Evotec’s UK kidney biobank, NURTuRE. Under the terms of the a...